Skip to main content
. 2022 Jan 29;11(4):454–466. doi: 10.1002/cpdd.1038

Figure 2.

Figure 2

Covariate evaluation of pemigatinib oral clearance using final population PK model for (A) demographic variables, (B) drug‐related variables, and (C) concomitant medications. Data represent GMR ± 90%CI for CL/F. CI, confidence interval; CL/F, apparent oral clearance; CYP, cytochrome P450; FGFR2, fibroblast growth factor receptor 2; GMR, geometric mean ratio; PK, pharmacokinetics.